➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Express Scripts
McKesson
AstraZeneca
Merck

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MANGANESE CHLORIDE IN PLASTIC CONTAINER

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Manganese Chloride In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03989310 ↗ An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer Recruiting Chinese PLA General Hospital Phase 1/Phase 2 2019-03-01 The outcome of pancreatic cancer is extremely poor. NCCN guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen, but the response rate is unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This one-arm, phase I/II study is designed to assess the safety and efficacy of Manganese primed combined therapy of anti-PD-1 antibody and chemotherapy.
NCT03989336 ↗ An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer Recruiting Chinese PLA General Hospital Phase 1/Phase 2 2019-03-01 Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. Platinum-containing chemotherapy has been widely adopted as a standard treatment for advanced ovarian cancer, the response rates in patients with relapsed/refractory ovarian cancer is unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This two-arm, phase I/II study is designed to assess the safety and efficacy of combined therapy of anti-PD-1 antibody and chemotherapy with or without Manganese priming.
NCT03991559 ↗ A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas Recruiting Chinese PLA General Hospital Phase 1 2018-11-01 Identification of T cell inhibitory signals, including PD-1/PD-L1, has prompted the development of a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which enable providing several therapeutic targets and tailoring of combinations of immune therapies. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This study is a first-in-man, Phase I, 3 + 3 dose escalation study of a combined regimen of Manganese and anti-PD-1 antibody with or without chemotherapies in subjects with unresectable/ metastatic solid tumors or lymphomas. This study is designed to assess the safety, tolerability, pharmacokinetic profile (PK profile), mode of delivery and Recommended Phase 2 Dose (RP2D) of this regimen.
NCT04004234 ↗ An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC Recruiting Chinese PLA General Hospital Phase 1/Phase 2 2019-03-01 Biliary tract cancer (BTC) is a rare heterogeneous collection of malignancies arising within the biliary tract, characterized by innate chemoresistance and abysmal prognosis. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This open-label, phase I/II study is designed to assess the safety and efficacy of Manganese primed combined therapy of anti-PD-1 antibody and gemcitabine/cisplatin chemotherapy.
NCT04119843 ↗ Safety and Diagnostic Efficacy of Mangoral in Patients With Abnormal Liver Cells and Reduced Kidney Function Not yet recruiting Ascelia Pharma AB Phase 3 2019-11-01 The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in patients with known or suspected focal liver lesions and severe renal impairment. The diagnostic efficacy of Mangoral will be assessed in terms of visualization of detected focal liver lesions in combined MRI (CMRI: combined Mangoral-enhanced and unenhanced MRI) compared to unenhanced MRI.
NCT04873440 ↗ An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma Recruiting Chinese PLA General Hospital Phase 1/Phase 2 2021-05-06 Radiotherapy is a regular care for metastatic solid tumors or lymphoma, and it can induce immunogenic death of tumor cells and a stronger immune response. Sometimes, tumor regression would be observed at sites distant to an irradiated field because of the radiotherapy-induced anticancer immune responses, so-called abscopal response. Manganese has been confirmed to activate innate immune and function as anticancer immunoadjuvant in pre-clinical studies. This study is designed to assess the abscopal response and safety of combined therapy of manganese and radiotherapy in patients with metastatic solid tumors or lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Manganese Chloride In Plastic Container

Condition Name

Condition Name for Manganese Chloride In Plastic Container
Intervention Trials
Lymphoma 2
Solid Tumor 2
Ovarian Cancer 1
Known or Suspected Focal Liver Lesions and Severe Renal Impairment 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Manganese Chloride In Plastic Container
Intervention Trials
Lymphoma 2
Ovarian Neoplasms 1
Carcinoma, Ovarian Epithelial 1
Pancreatic Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Manganese Chloride In Plastic Container

Trials by Country

Trials by Country for Manganese Chloride In Plastic Container
Location Trials
China 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Manganese Chloride In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Manganese Chloride In Plastic Container
Clinical Trial Phase Trials
Phase 3 1
Phase 1/Phase 2 4
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Manganese Chloride In Plastic Container
Clinical Trial Phase Trials
Recruiting 5
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Manganese Chloride In Plastic Container

Sponsor Name

Sponsor Name for Manganese Chloride In Plastic Container
Sponsor Trials
Chinese PLA General Hospital 5
Ascelia Pharma AB 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Manganese Chloride In Plastic Container
Sponsor Trials
Other 5
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKinsey
Colorcon
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.